14th July 2015: Dr Richard Bax Senior Partner of TranScrip has been appointed to the Board of Directors.
This new antibiotic research company has been set up with approximately $3million US in capital. The capital will be invested into research into novel antibiotics for resistant Gram negative infections. Investors include Merck Lumira and SR1.
For further detail, please see the press release below.